IONS Q3 2024 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$134M-7.2% YoY

Gross Profit

$133M99.2% margin

Operating Income

-$149M-111.1% margin

Net Income

-$140M-105.0% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

-40.6%

Cash Flow

Operating Cash Flow

-$115M

Free Cash Flow

-$124M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.4B

Stockholders' Equity

$662M

Cash & Equivalents

$335M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$134M	$144M	-7.2%
Gross Profit	$133M	$142M	-6.5%
Operating Income	-$149M	-$143M	-3.8%
Net Income	-$140M	-$147M	+4.7%

Revenue Segments

Commercial

$76M29%

Research and Development Revenue

$58M22%

SPINRAZA Royalties

$57M22%

Collaborative Agreement Revenue

$45M17%

Other Commercial

$13M5%

Product

$9M3%

Licensing and Other Royalties

$4M2%